Anthera Pharmaceuticals Inc - FORM 10-K - EX-23.2 - EXHIBIT 23.2 - March 16, 2015

Attached files

file filename
EX-10.34 - EXHIBIT 10.34 - Anthera Pharmaceuticals Incex10_34.htm
EX-10.31 - EXHIBIT 10.31 - Anthera Pharmaceuticals Incex10_31.htm
EX-10.33 - EXHIBIT 10.33 - Anthera Pharmaceuticals Incex10_33.htm
EX-10.23 - EXHIBIT 10.23 - Anthera Pharmaceuticals Incex10_23.htm
EXCEL - IDEA: XBRL DOCUMENT - Anthera Pharmaceuticals IncFinancial_Report.xls
EX-32.1 - EXHIBIT 32.1 - Anthera Pharmaceuticals Incex32_1.htm
EX-23.1 - EXHIBIT 23.1 - Anthera Pharmaceuticals Incex23_1.htm
EX-32.2 - EXHIBIT 32.2 - Anthera Pharmaceuticals Incex32_2.htm
EX-10.36 - EXHIBIT 10.36 - Anthera Pharmaceuticals Incex10_36.htm
EX-10.35 - EXHIBIT 10.35 - Anthera Pharmaceuticals Incex10_35.htm
EX-31.2 - EXHIBIT 31.2 - Anthera Pharmaceuticals Incex31_2.htm
10-K - FOR THE FISCAL YEAR ENDED DECEMBER 31, 2014 - Anthera Pharmaceuticals Inca3615010k.htm
EX-31.1 - EXHIBIT 31.1 - Anthera Pharmaceuticals Incex31_1.htm
Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 

We consent to the incorporation by reference in Registration Statements No. 333-165714, No. 333-168970, No. 333-172100, No. 333-180144, No. 333-188679 and No. 333-196740 on Form S-8, No. 333-175095, No. 333-187771 and No. 333-187780 on Form S-3, of our report dated March 26, 2013 (March 28, 2014 as to the effects of the restatement and the reverse stock split discussed in Notes 13 and 1, respectively, to the consolidated financial statements), relating to the consolidated financial statements of Anthera Pharmaceuticals, Inc., (which report expresses an unqualified opinion and includes an explanatory paragraph relating to the restatement discussed in Note 13) appearing in this Annual Report on Form 10-K of Anthera Pharmaceuticals, Inc. for the year ended December 31, 2014.

/s/ Deloitte & Touche LLP

San Francisco, California
March 16, 2015

 
 

Anthera Pharmaceuticals Inc Reports